Tle1 tumor suppressor negatively regulates inflammation in vivo and modulates NF-κB inflammatory pathway

Area of Science:

• Molecular Biology
• Immunology
• Developmental Biology

Background:

• Transducin-like enhancer of split 1 (Tle1) is a corepressor involved in various cellular functions.
• Limited physiological studies exist on Tle1's role in vivo.
• Tle1 interacts with DNA-binding transcription factors, influencing gene expression.

Purpose of the Study:

• To investigate the physiological role of Tle1 in vivo.
• To determine Tle1's function in regulating inflammation and immune responses.
• To explore Tle1's potential involvement in cancer progression.

Main Methods:

• Generation and analysis of Tle1-deficient (Tle1(Δ/Δ)) mice.
• Assessment of inflammatory markers (cytokines, chemokines) in tissues and circulation.
• Macrophage stimulation assays with Toll-like receptor (TLR) agonists and lipopolysaccharides (LPS).
• Evaluation of inflammatory response to 12-O-tetradecanoylphorbol-13-acetate (TPA) treatment.
• Analysis of NF-κB and Hes1 signaling pathways.
• Assessment of melanoma xenograft growth in Tle1(Δ/Δ) mice.

Main Results:

• Tle1(Δ/Δ) mice exhibit skin defects, lung hypoplasia, runting, and early mortality.
• A chronic inflammatory phenotype is observed, with increased inflammatory cytokines and chemokines.
• Tle1 deficiency leads to elevated IL-6 and G-CSF, and a myeloid cell shift.
• Tle1(Δ/Δ) macrophages show heightened inflammatory cytokine production upon TLR agonist/LPS stimulation.
• Loss of Tle1 results in increased NF-κB activation and decreased Hes1 expression.
• Tle1(Δ/Δ) mice display accelerated B6-F10 melanoma xenograft growth.

Conclusions:

• Tle1 is a critical in vivo counterregulator of inflammation.
• Tle1 deficiency exacerbates inflammatory responses and promotes tumor growth.
• Tle1 plays a significant role in inflammatory diseases and cancer progression.
• Further research into Tle1's therapeutic potential in inflammation and cancer is warranted.